Capricor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. 

CEO
Linda Marbán
CEOLinda Marbán
Employees
231
Employees231
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1996
Founded1996
Employees
231
Employees231

CAPR Key Statistics

Market cap
1.45B
Market cap1.45B
Price-Earnings ratio
-10.83
Price-Earnings ratio-10.83
Dividend yield
Dividend yield
Average volume
861.32K
Average volume861.32K
High today
High today
Low today
Low today
Open price
$25.36
Open price$25.36
Volume
0.00
Volume0.00
52 Week high
$40.37
52 Week high$40.37
52 Week low
$4.30
52 Week low$4.30

Stock Snapshot

Capricor(CAPR) stock is priced at $25.04, giving the company a market capitalization of 1.45B. It carries a P/E multiple of -10.83.

During the trading day, Capricor(CAPR) stock saw an opening price of $25.36, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 861.32K.

Over the past 52 weeks, Capricor(CAPR) stock has traded between a high of $40.37 and a low of $4.30.

Over the past 52 weeks, Capricor(CAPR) stock has traded between a high of $40.37 and a low of $4.30.

CAPR News

Simply Wall St 5d
Why Capricor Therapeutics Is Down 10.8% After FDA Clears Key Deramiocel Inspection Step

Capricor Therapeutics recently cleared a key hurdle for its lead Duchenne muscular dystrophy therapy Deramiocel, completing an FDA Pre-License Inspection at its...

Why Capricor Therapeutics Is Down 10.8% After FDA Clears Key Deramiocel Inspection Step

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CAPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.